Caplin Point Laboratories Limited (CAPLIPOINT)
Healthcare | Drug Manufacturers - Specialty & Generic
₹2177.35
-0.82% (₹17.9)
Market Overview
| Market Cap | 165504073728 |
| Volume | 91673 |
| 52W High | ₹2641.0 |
| 52W Low | ₹1225.0 |
Key Ratios
| P/E Ratio | 33.736443 |
| EPS | 64.54 |
| Beta | 0.399 |
| Dividend Yield | 0.0023% |
Financial Performance
Revenue Growth
0.178%
Profit Margin
0.26929%
ROE
0.21243%
ROA
0.12741%
Stock Analysis Score: 70/100
Growth Score: 70/100
Key Strengths:
- Excellent profit margins above 15%
- Strong ROE above 15%
- High PE ratio between 25-35
- Low volatility with beta below 1
- Strong operating margins above 15%
Recommendation
Buy - The stock shows good fundamentals with some room for improvement
Detailed Analysis
Growth: 0.2% revenue growth indicates weak business expansion.
Profitability: 26.9% profit margin shows excellent operational efficiency.
Returns: ROE of 21.2% demonstrates strong return on shareholder investment.
Valuation: PE ratio of 33.7x is expensive compared to market averages.
Trading Decision Guide
- Score 80-100: Consider for long-term investment with high conviction
- Score 60-79: Suitable for medium-term investment with regular monitoring
- Score 40-59: Short-term trading opportunities, maintain strict stop-losses
- Score Below 40: High-risk trading only, thorough research essential
Risk Factors
- Market Cap: ₹16550.4Cr
- Beta: 0.40 (Market Volatility)
- 52-Week Range: ₹1225.0 - ₹2641.0
Last Updated: 2025-01-23 06:58:00